Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014

被引:8
|
作者
Pedraza-Serrano, Fernando [1 ]
Jimenez-Garcia, Rodrigo [2 ]
Lopez-de-Andres, Ana [2 ]
Hernandez-Barrera, Valentin [2 ]
Esteban-Hernandez, Jesus [2 ]
Sanchez-Munoz, Gema [1 ]
Puente-Maestu, Luis [1 ]
de-Miguel-Diez, Javier [1 ]
机构
[1] UCM, Inst Invest Sanitaria Gregorio Maranon IiSGM, Hosp Gen Univ Gregorio Maranon, Resp Dept,Fac Med, Madrid, Spain
[2] Rey Juan Carlos Univ, Hlth Sci Fac, Prevent Med & Publ Hlth Teaching & Res Unit, Madrid, Spain
关键词
Idiopathic pulmonary fibrosis; Comorbidities; Charlson comorbidity index; Elixhauser comorbidity index; In-hospital mortality; BODY-MASS INDEX; INTERSTITIAL LUNG-DISEASES; SURVIVAL; PREVALENCE; EMPHYSEMA; OUTCOMES; HYPERTENSION; BURDEN; IMPACT;
D O I
10.1016/j.rmed.2018.04.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To describe and compare the comorbid conditions, the in-hospital mortality (IHM) and the length of hospital stay (LOHS) among idiopathic pulmonary fibrosis (IPF) patients and non-IPF-matched patients hospitalized in Spain. We assess the performance of the Charlson Comorbidity Index[CCI] and the Elixhauser Comorbidity Index[ECI] to predict IHM in IPF and we identify the specific predictive factors of IHM in patients suffering IPF. Methods: We identified patients with IPF hospitalized in years 2002, 2006, 2010 and 2014. Cases of IPF were matched with non-IPF controls by sex, age, province of residence and year. Data were collected from the Spanish National Hospital Discharge Database. Results: We identified 10,285 hospitalizations with IPF, evidencing an increase in the number of IPF patients from 2002 to 2014. Overtime the prevalence of comorbidities included in the CCI significantly increased in patients with IPF, exception made of myocardial infarction and dementia. The prevalence of comorbidities included in the ECI, except paralysis and peptic ulcer disease excluding bleeding, increased significantly overtime. LOHS was longer among IPF patients than non-IPF controls and decreased significantly from 2002 to 2014. IHM was significantly higher in patients with IPF (adjustedOR 1.97; 95% CI 1.77-2.19). Area under the ROC curves showed that ECI model had a better performance to predict IHM than CCI. Conclusions: The incidence of hospitalizations for IPF increased significantly from 2002 to 2014. We observed an increase overtime of most of the comorbidities included in CCI and ECI. LOHS and IHM were higher in patients with IPF than in non-IPF controls.
引用
下载
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [31] Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis
    Cocconcelli, E.
    Cerri, S.
    Spagnolo, P.
    Tonelli, R.
    Ventura, P.
    Abbati, G.
    Vegetti, A.
    Pileri, F.
    Del Giovane, C.
    Balduzzi, S.
    Pietrangelo, A.
    Richeldi, L.
    Luppi, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [32] Comorbidities and mortality among patients with chronic obstructive pulmonary disease
    Skajaa, Nils
    Laugesen, Kristina
    Horvath-Puho, Erzsebet
    Sorensen, Henrik Toft
    BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
  • [33] High antinuclear antibody titer is associated with increased mortality risk in patients with idiopathic pulmonary fibrosis
    Izhakian, Shimon
    Igawa, May
    Kramer, Mordechai R.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [34] High antinuclear antibody titer is associated with increased mortality risk in patients with idiopathic pulmonary fibrosis
    Izhakian, Shimon
    Igawa, May
    Zion, Liora Chen
    Mekiten, Ori
    Freidkin, Lev
    Rosengarten, Dror
    Heching, Moshe
    Kramer, Mordechai Reuven
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [35] Integrated Baseline And Longitudinal Mortality Risk Prediction In Idiopathic Pulmonary Fibrosis
    Ley, B.
    Bradford, W. Z.
    Weycker, D.
    Vittinghof, E.
    Du Bois, R. M.
    Collard, H. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [36] Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
    Divo, Miguel
    Cote, Claudia
    de Torres, Juan P.
    Casanova, Ciro
    Marin, Jose M.
    Pinto-Plata, Victor
    Zulueta, Javier
    Cabrera, Carlos
    Zagaceta, Jorge
    Hunninghake, Gary
    Celli, Bartolome
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (02) : 155 - 161
  • [37] Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis
    Mochizuka, Yasutaka
    Suzuki, Yuzo
    Kono, Masato
    Hasegawa, Hirotsugu
    Hashimoto, Dai
    Yokomura, Koshi
    Inoue, Yusuke
    Yasui, Hideki
    Hozumi, Hironao
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Inui, Naoki
    Nakamura, Hidenori
    Suda, Takafumi
    RESPIROLOGY, 2023, 28 (08) : 775 - 783
  • [38] Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation
    Vianello, Andrea
    Molena, Beatrice
    Turato, Cristian
    Braccioni, Fausto
    Arcaro, Giovanna
    Paladini, Luciana
    Andretta, Margherita
    Saetta, Marina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1187 - 1190
  • [39] ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN SPAIN: RESULTS FROM THE OASIS STUDY
    Villar, A.
    Cano-Jimenez, E.
    Romero Ortiz, A. D.
    Rodriguez Nieto, M. J.
    Ramon, A.
    Armengol, S.
    Alhaja, E.
    Morros, M.
    Artes, M.
    VALUE IN HEALTH, 2020, 23 : S712 - S712
  • [40] Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
    Ian Glaspole
    Francesco Bonella
    Elena Bargagli
    Marilyn K. Glassberg
    Fabian Caro
    Wibke Stansen
    Manuel Quaresma
    Leticia Orsatti
    Elisabeth Bendstrup
    Respiratory Research, 22